Amgen Inc. (AMGN)
|Net Income (ttm)||7.09B|
|Trading Day||May 7|
|Day's Range||251.65 - 255.73|
|52-Week Range||207.32 - 274.65|
THOUSAND OAKS, Calif., May 6, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m.
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaqu...
THOUSAND OAKS, Calif., May 5, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sND...
There are certainly some problem spots for the big biotech.
The near future looks concerning for these companies in three different sectors. But for long-term investors, that can create opportunities.
Amgen's Q1 results didn't bode well with the investors and the stock plunged over 7% in Wednesday's trading session (April 28). But now that the stock has fallen 9% in just five days, will AMGN stock re...
Despite disappointing results that missed expectations, progress with an important new cancer drug saved the day.
Nobody seemed impressed by the company's latest quarterly results.
Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.
Amgen Inc (NASDAQ: AMGN) has a rough start this year after its Q1 March-quarter revenue slipped 4% from the year-ago quarter, while its earnings fell about 10%. Earnings: Even though unit volumes grew 4...
COVID-19 continued to negatively impact the big biotech.
THOUSAND OAKS, Calif., April 28, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing ...
Amgen (AMGN) delivered earnings and revenue surprises of -7.50% and -5.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
U.S. biotech Amgen Inc on Tuesday said its first-quarter sales and profit fell due to a 7% drop in its net drug prices and the COVID-19 pandemic, which continued to limit patient interactions with healt...
THOUSAND OAKS, Calif., April 27, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2021.
Amgen just bought Rodeo Therapeutics in a move that bolsters its drug candidate pipeline.
OTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psori...
THOUSAND OAKS, Calif., April 23, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis rega...
Bristol-Myers Squibb Co (NYSE: BMY) has announced new data from its two Phase 3 trials POETYK PSO-1 and POETYK PSO-2 for deucravacitinib, its oral, selective TYK2 inhibitor for moderate to severe plaque...
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.
THOUSAND OAKS, Calif., April 22, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 27, 2021, after the close of the U.S. ...
PRESS RELEASE: REGULATED INFORMATION 22 April 2021, 07:01 CEST
Strategas' Chris Verrone lays out his hide-out trades
Strategas' Chris Verrone says brace yourself for market weakness. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Dan Nathan and Pete Najarian.
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA has granted Breakthrough Therapy Designation to Amgen Inc's (NASDAQ: AMGN) bemarituzumab for patients with gastric and gastroesophageal (GEJ) adenocarcinoma. The designation covers bemarituzumab...
THOUSAND OAKS, Calif., April 19, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for investigational be...
Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biom...
THOUSAND OAKS, Calif., April 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of Biomarker Assist™ , a program to help more patients with metastatic (stage IV) non-small cell lun...
THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of c...
Investment company Resource Planning Group (Current Portfolio) buys Amgen Inc, BTC iShares MSCI Emerging Markets Min Vol Factor E, Vanguard Small Cap Value ETF, Vanguard Value ETF, Schwab Fundamental In...
Amgen (AMGN) inks an agreement to acquire privately held company, Rodeo Therapeutics Corporation, to boost its inflammation portfolio.
The news: Pharmaceutical giant Amgen agreed to acquire Rodeo Therapeutics, a Seattle biotech startup creating small-molecule therapies that help repair and regrow tissues.
With blockbuster immunology treatments Enbrel (via $16 billion acquisition of Immunex in 2009) and Otezla (added in 2013 via $13 billion deal) already in its bag, Amgen Inc (NASDAQ: AMGN) has now put it...
THOUSAND OAKS, Calif. and SEATTLE, March 30, 2021 /PRNewswire/ -- Amgen Inc. (NASDAQ:AMGN) and Rodeo Therapeutics Corporation (Rodeo) today announced an agreement under which Amgen will acquire Rodeo, a...
Though most people reinvest dividend payments from blue chips, you can use them to live on while still growing your principal.
The drugmaker needs as much potential revenue as it can acquire at a reasonable price.
In Amgen Inc.'s (NASDAQ:AMGN) recent agreement to buy small cancer drug developer Five Prime Therapeutics Inc. (NASDAQ:FPRX) for nearly $2 billion, there seems to be a message for investors in other sma...
Earlier this month, biotech giant Amgen Inc (NASDAQ: AMGN) announced a $1.9 billion buyout of Five Prime Therapeutics Inc (NASDAQ: FPRX) that outlasted around 15 potential collaborators. Background: Amg...
With the first quarter soon coming to an end, many investors are looking to print some solid gains for the first three months of 2021, while turning their attention to what could be a very strong second...
It's not getting much attention lately, but the future for Amgen looks strong.
THOUSAND OAKS, Calif., March 11, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at 2:30 p.m.
Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, Amgen's revenue was $25.42 billion, an increase of 8.83% compared to the previous year's $23.36 billion. Earnings were $7.26 billion, a decrease of -7.37%.
According to 30 analysts, the average rating for Amgen stock is "Buy." The 12-month stock price forecast is 254.40, which is an increase of 0.07% from the latest price.